Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia

Haematologica

Volumn 99, Issue 8, 2014, Pages 1312-1316

  Sakaguchi, Hirotoshi ^a,b   Nishio, Nobuhiro ^a   Hama, Asahito ^a   Kawashima, Nozomu ^a   Wang, Xinan ^a   Narita, Atsushi ^a   Doisaki, Sayoko ^a   Xu, Yinyan ^a   Muramatsu, Hideki ^a   Yoshida, Nao ^b   Takahashi, Yoshiyuki ^a   Kudo, Kazuko ^c   Moritake, Hiroshi ^d   Nakamura, Kazuhiro ^e   Kobayashi, Ryoji ^f   Ito, Etsuro ^g   Yabe, Hiromasa ^h   Ohga, Shouichi ⁱ   Ohara, Akira ^j   Kojima, Seiji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f SAPPORO HOKUYU HOSPITAL   (Japan)

^g HIROSAKI UNIVERSITY   (Japan)

^h TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; APLASTIC ANEMIA; ARTICLE; BLOOD ANALYSIS; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; SCHOOL CHILD; TELOMERE HOMEOSTASIS; ANEMIA, APLASTIC; DRUG EFFECTS; IMMUNOLOGY; INFANT; PATHOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PRESCHOOL CHILD; TELOMERE; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA, APLASTIC; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LYMPHOCYTES; MALE; PREDICTIVE VALUE OF TESTS; TELOMERE; TELOMERE HOMEOSTASIS; TREATMENT OUTCOME;

EID: 84905181415     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.091165     Document Type: Article

References (32)

1. Kojima S, Horibe K, Inaba J, Yoshimi A, Takahashi Y, Kudo K, et al. Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol. 2000; 111(1): 321-8.
2. Young NS. Acquired aplastic anemia. JAMA. 1999; 282(3): 271-8.
3. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colonystimulating factor in children with acquired aplastic anemia. Blood. 2000; 96(6): 2049-54.
4. Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005; 106 (6): 2102-4.
5. Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1): 11-8.
6. Nakao S, Takamatsu H, Chuhjo T, Ueda M, Shiobara S, Matsuda T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994; 84(12): 4257-61.
7. Maciejewski JP, Follmann D, Nakamura R, Saunthararajah Y, Rivera CE, Simonis T, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood. 2001; 98(13): 3513-9.
8. Oguz FS, Yalman N, Diler AS, Oguz R, Anak S, Dorak MT. HLA-DRB1*15 and pediatric aplastic anemia. Haematologica. 2002; 87(7): 772-4.
9. Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-CD59-blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006; 107: 1308-14.
10. Yoshida N, Yagasaki H, Takahashi Y, Yamamoto T, Liang J, Wang Y, et al. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuriatype cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia. Br J Haematol. 2008; 142 (3): 427-35.
11. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009; 144(2): 206-16.
12. Walne AJ, Dokal I. Advances in the understanding of dyskeratosis congenita. Br J Haematol. 2009; 145: 164-72.
13. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985; 43(2 Pt 1): 405-13.
14. Szostak JW, Blackburn EH. Cloning yeast telomeres on linear plasmid vectors. Cell. 1982; 29(1): 245-55.
15. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999; 402: 551-5.
16. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009; 361: 2353-65.
17. Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005; 352(14): 1413-24.
18. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood. 2006; 107: 2680-5.
19. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood. 1998; 91(10): 3582-92.
20. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001; 97(4): 895-900.
21. Yamaguchi H, Baerlocher GM, Lansdorp PM, Chanock SJ, Nunez O, Sloand E, Young NS. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood. 2003; 102 (3): 916-8.
22. Leteurtre F, Li X, Guardiola P, Le Roux G, Sergère JC, Richard P, et al. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br J Haematol. 1999; 105(4): 883-93.
23. Pavesi E, Avondo F, Aspesi A, Quarello P, Rocci A, Vimercati C, et al. Analysis of telomeres in peripheral blood cells from patients with bone marrow failure. Pediatr Blood Cancer. 2009; 53(3): 411-6.
24. Thornley I, Dror Y, Sung L, Wynn RF, Freedman MH. Abnormal telomere shortening in leucocytes of children with Shwachman-Diamond syndrome. Br J Haematol. 2002; 117(1): 189-92.
25. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of Telomere Length of Peripheral Blood Leukocytes With Hematopoietic Relapse, Malignant Transformation, and Survival in Severe Aplastic Anemia. JAMA. 2010; 304 (12): 1358-64.
26. Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood. 2008; 111: 1054-9.
27. Takahashi Y, Muramatsu H, Sakata N, Hyakuna N, Hamamoto K, Kobayashi R, et al. Rabbit antithymocyte globulin and cyclosporine as first-line therapy for children with acquired aplastic anemia. Blood. 2013; 121: 862-3.
28. Baerlocher GM, Vulto I, de Jong G, Lansdorp PM. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc. 2006; 1(5): 2365-76.
29. Alter BP, Baerlocher GM, Savage SA, Chanock SJ, Weksler BB, Willner JP, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2007; 110(5): 1439-47.
30. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990; 345(6274): 458-60.
31. Nishio N, Kojima S. Recent progress in dyskeratosis congenita. Int J Hematol. 2010; 92(3): 419-24.
32. Yoshida N, Yagasaki H, Hama A, Takahashi Y, Kosaka Y, Kobayashi R, et al. Predicting response to immunosuppressive therapy in childhood aplastic anemia. Haematologica. 2011; 96(5): 771-4.